The circadian clock gene PER2 enhances chemotherapeutic efficacy in nasopharyngeal carcinoma when combined with a targeted nanosystem.
Li HouHai-Liang LiHai-Yan WangDede MaJing LiuLiqiong MaZhihua WangZhihua YangFa-Xuan WangXe-Chun XiaPublished in: Journal of materials chemistry. B (2021)
Treatment failure occurs in more than 40% of advanced nasopharyngeal carcinoma (NPC) patients including local recurrence and distant metastasis due to chemoradioresistance. Circadian clock genes were identified as regulating cancer progression and chemoradiosensitivity in a time-dependent manner. A novel nanosystem can ensure the accumulation and controllable release of chemotherapeutic agents at the tumour site at a set time. In this study, we investigated the expression of circadian clock genes and identified that period circadian regulator 2 (PER2) as a tumour suppressor plays a key role in NPC progression. A label-free proteomic approach showed that PER2 overexpression can inhibit the ERK/MAPK pathway. The chemotherapeutic effect of PER2 overexpression was assessed in NPC together with the nanosystem comprising folic acid (FA), upconverting nanoparticles covalently coupled with Rose Bengal (UCNPs-RB), 10-hydroxycamptothecin (HCPT) and lipid-perfluorohexane (PFH) (FURH-PFH-NPs). PER2 overexpression combined with the targeted and controlled release of nanoagents elevated chemotherapeutic efficacy in NPC, which has potential application value for the chronotherapy of tumours.
Keyphrases
- label free
- cell proliferation
- transcription factor
- genome wide identification
- genome wide
- end stage renal disease
- signaling pathway
- ejection fraction
- newly diagnosed
- cancer therapy
- pi k akt
- chronic kidney disease
- papillary thyroid
- poor prognosis
- peritoneal dialysis
- prognostic factors
- copy number
- genome wide analysis
- patient reported outcomes
- fatty acid
- human health
- young adults
- atomic force microscopy
- binding protein
- bioinformatics analysis
- single molecule
- risk assessment